BioWorld Asia

April 11, 2007

Affimed Raises $33.5M For TandAbs In Oncology

Affimed Therapeutics AG raised €25 million (US$33.5 million) in a Series B round to fund its two lead programs, in non-Hodgkins lymphoma (NHL) and Hodgkin's disease. Each is in preclinical development at present. (BioWorld International) Read More

Stem Cells Sciences Raises $9.9M With New ASX Listing

Innate Immunity, New Combo Of Antibiotics Fight Resistance

Patients' Group Voices Anger At Advanced Therapies Tactic

Atlantic Closes First Deal, Licensing GI Compound

Nokad Obtains Its First Functional KOs in Rats

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 23, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

Photo of two people shaking hands near lab equipment

K2 nabs two Antengene bispecific TCEs in $2B license, option deal

BioWorld

MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene...

In the clinic for June 22, 2026

BioWorld

Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...